Castle Biosciences CSTL Operating Expenses, Net Of Other Operating Income
Operating Expenses, Net Of Other Operating Income at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept cstl:OperatingExpensesNetOfOtherOperatingIncome.
The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Castle Biosciences's operating expenses, net of other operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Castle Biosciences's operating expenses, net of other operating income?
- Castle Biosciences (CSTL) reported operating expenses, net of other operating income of $102.09M in Q1 2026.
- How has Castle Biosciences's operating expenses, net of other operating income changed year-over-year?
- Castle Biosciences's operating expenses, net of other operating income decreased by 11.9% year-over-year, from $115.92M to $102.09M.
- What is the long-term trend for Castle Biosciences's operating expenses, net of other operating income?
- Over 4 years (2021 to 2025), Castle Biosciences's operating expenses, net of other operating income has grown at a 30.3% compound annual growth rate (CAGR), from $134.16M to $387.04M.
- What does operating expenses, net of other operating income mean?
- This metric represents the total costs incurred by the company to support its core business operations, including research and development, sales, marketing, and general administrative functions, adjusted for any miscellaneous operating income. It serves as a primary indicator of the company's operational burn rate and the efficiency with which it manages its overhead relative to its commercial activities. Monitoring this figure helps investors assess the scalability of the business model and the company's ability to control costs while pursuing growth in its specialized diagnostic markets.